MedTrace Logo

Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study

NCT00229697 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 317

Last updated 2015-10-05

No results posted yet for this study

Summary

This study is being carried out to see if ZD1839 is effective in treating metastatic breast cancer in combination with Nolvadex, and if so, how it compares with Nolvadex alone.

Conditions

  • Breast Neoplasms

Interventions

DRUG

Gefitinib

DRUG

Tamoxifen

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca Iressa Medical Science Director, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-10-31
Primary Completion
2006-12-31
Completion
2015-06-30

Countries

  • United States
  • Argentina
  • Australia
  • Belgium
  • Brazil
  • Canada
  • Denmark
  • France
  • Germany
  • South Africa
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00229697 on ClinicalTrials.gov